Cocaine-induced ANCA-associated renal disease: a case-based review.
ANCA-associated vasculitis
Cocaine
Glomerulonephritis
Levamisole
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
09
05
2019
accepted:
31
07
2019
pubmed:
12
8
2019
medline:
28
4
2020
entrez:
12
8
2019
Statut:
ppublish
Résumé
Idiopathic antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV) are a group of diseases that are often difficult to diagnose due to the wide range of clinical manifestations. Notably, renal involvement is a serious organ complication, which usually requires intensive immunosuppressive therapy and is prone to recurrence. In recent years, there has been some progress regarding the understanding of the pathogenesis of the diseases. It has been shown that both cocaine and levamisole, which is a common adulterant of cocaine, can trigger the formation of ANCAs and lead to the corresponding symptoms. We report two cases of AAV with different renal manifestations associated with cocaine consumption. Furthermore, we performed a review of the literature to identify, characterize and describe histologically documented cases of renal involvement in AAV, related to cocaine abuse. Cocaine/levamisole-induced vasculitis may, therefore, mimic idiopathic AAV. Although the detection of ANCA and anti-PR3 (proteinase 3, PR3) as well as anti-MPO antibodies (myeloperoxidase, MPO) are the serological hallmark of idiopathic AAV, certain clinical- and antibody constellations should lead to consideration of illicit drugs as inductors of the disease. Especially in young patients, certain serologic constellations (e.g., PR3 and MPO double positivity, positive antinuclear antibodies, low complement level, and positive testing for antiphospholipid antibodies), skin involvement, musculoskeletal symptoms and hematologic (anemia, leukopenia) affections should prompt testing for cocaine and levamisole consumption via urine drug testing. Treatment includes both immunosuppressive approaches and drug cessation but is difficult since many patients continue cocaine consumption.
Identifiants
pubmed: 31401698
doi: 10.1007/s00296-019-04410-9
pii: 10.1007/s00296-019-04410-9
doi:
Substances chimiques
Antibodies, Antineutrophil Cytoplasmic
0
Cocaine
I5Y540LHVR
Types de publication
Case Reports
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2005-2014Références
J Anal Toxicol. 2002 Oct;26(7):393-400
pubmed: 12422991
Case Rep Nephrol. 2015;2015:372413
pubmed: 26290761
J Thromb Thrombolysis. 2012 Jul;34(1):7-10
pubmed: 22437653
Rheumatology (Oxford). 2017 Apr 1;56(4):638-643
pubmed: 27354687
Curr Opin Rheumatol. 2013 Jan;25(1):50-5
pubmed: 23196324
Autoimmun Rev. 2010 Oct;9(12):812-9
pubmed: 20656070
Am J Emerg Med. 2000 Sep;18(5):593-8
pubmed: 10999576
J Oral Pathol Med. 2013 Aug;42(7):507-16
pubmed: 23301777
BMC Nephrol. 2019 Mar 20;20(1):99
pubmed: 30894132
Conn Med. 2015 Jun-Jul;79(6):343-6
pubmed: 26263714
Clin Kidney J. 2014 Dec;7(6):513-7
pubmed: 25859366
Medicine (Baltimore). 2014 Oct;93(17):290-297
pubmed: 25398064
Am J Nephrol. 2017;45(3):209-216
pubmed: 28132051
Am J Clin Pathol. 2016 May;145(5):720-6
pubmed: 27247374
Nefrologia. 2016;36(1):76-8
pubmed: 26620419
Braz J Med Biol Res. 2016;49(5):e5244
pubmed: 27119429
Ann Transl Med. 2015 Oct;3(18):271
pubmed: 26605317
J Clin Rheumatol. 2019 Apr;25(3):e16-e26
pubmed: 29782427
Pathol Res Pract. 2016 Jul;212(7):650-3
pubmed: 27067665
Drug Test Anal. 2011 Feb;3(2):89-96
pubmed: 21322119
Curr Opin Rheumatol. 2014 Jan;26(1):42-9
pubmed: 24276086
Ear Nose Throat J. 1996 Sep;75(9):623-6
pubmed: 8870370
Joint Bone Spine. 2018 Jan;85(1):9-14
pubmed: 28602438
J Anal Toxicol. 2011 Apr;35(3):176-8
pubmed: 21439154
Case Rep Pulmonol. 2015;2015:321539
pubmed: 25918664
Am J Pathol. 1989 Nov;135(5):921-30
pubmed: 2683800
J Forensic Sci. 2015 Mar;60(2):538
pubmed: 25754544
Acta Derm Venereol. 2008;88(6):594-6
pubmed: 19002345
N Engl J Med. 2001 Aug 2;345(5):351-8
pubmed: 11484693
Case Rep Med. 2015;2015:547023
pubmed: 26635879
Clin Toxicol (Phila). 2012 Apr;50(4):231-41
pubmed: 22455354
Lancet. 2004 Mar 6;363(9411):782
pubmed: 15016489
BMJ Case Rep. 2015 Aug 26;2015:
pubmed: 26311010
BMJ Case Rep. 2012 Aug 08;2012:
pubmed: 22879002
MMWR Morb Mortal Wkly Rep. 2009 Dec 18;58(49):1381-5
pubmed: 20019655
J Investig Med High Impact Case Rep. 2014 Sep 30;2(3):2324709614551557
pubmed: 26425622
Autoimmun Rev. 2018 Jan;17(1):73-77
pubmed: 29108823
Clin Kidney J. 2016 Apr;9(2):234-8
pubmed: 26985374
Curr Opin Rheumatol. 2008 Jan;20(1):35-9
pubmed: 18281855
N Engl J Med. 2013 Jun 20;368(25):2402-14
pubmed: 23782179
Semin Arthritis Rheum. 2019 Apr;48(5):921-926
pubmed: 30166200
Clin Nephrol Case Stud. 2014 Dec 15;3:37-41
pubmed: 29043132
BMJ Case Rep. 2018 Sep 19;2018:
pubmed: 30232205
J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2487-9
pubmed: 24910368
Clin J Am Soc Nephrol. 2011 Dec;6(12):2799-805
pubmed: 21980179
Clin Kidney J. 2015 Oct;8(5):482-8
pubmed: 26413270
Curr Rheumatol Rep. 2012 Dec;14(6):532-8
pubmed: 22875288
J Addict Med. 2017 Mar/Apr;11(2):157-160
pubmed: 28166084